Literature DB >> 25372796

Pulmonary hypertension and interstitial lung disease within PHAROS: impact of extent of fibrosis and pulmonary physiology on cardiac haemodynamic parameters.

A Fischer1, J J Swigris, M B Bolster, L Chung, M E Csuka, R Domsic, T Frech, M Hinchcliff, V Hsu, L K Hummers, M Gomberg-Maitland, S C Mathai, R Simms, V D Steen.   

Abstract

OBJECTIVES: We sought to examine the relationship between measures of ILD severity and PH in patients with SSc.
METHODS: We identified 55 subjects from 12 PHAROS sites with RHC-proven PH and HRCT evidence of ILD. Subjects with PH due to left heart disease were excluded. Baseline HRCT scans were scored by a standardised system that graded severity of ILD. Summary statistics were generated for baseline characteristics. Spearman correlation and linear regression were used to examine relationships between ILD and PH severity variables.
RESULTS: The majority of subjects were white women; nearly half had limited cutaneous SSc. Most subjects were New York Heart Association functional class II or III. Pulmonary function testing revealed moderate restriction (mean FVC 64.3 ± 17.2% predicted) with severe reduction in diffusing capacity (mean DLco 34.2 ± 13.3% predicted). RHC demonstrated mild to moderate PH (mean PAP 35 ± 9 mmHg, mean PVR 5.1 ± 3.7 WU). There was no correlation between severity of ILD (by either HRCT or PFT) and cardiac haemodynamic parameters of PH.
CONCLUSIONS: No association between severity of ILD and cardiac haemodynamic profiles were identified in this cohort. We believe this underscores the complex nature of PH and ILD in individuals with SSc. We do suspect that some individuals with SSc-ILD will also have concomitant pulmonary vascular disease but simple assessments to grade severity of ILD - by PFT or HRCT estimates of ILD extent - are likely not enough to reliably distinguish between PAH versus PH-ILD. Further research into how to distinguish and manage these subsets is warranted.

Entities:  

Mesh:

Year:  2014        PMID: 25372796

Source DB:  PubMed          Journal:  Clin Exp Rheumatol        ISSN: 0392-856X            Impact factor:   4.473


  8 in total

1.  Prevalence, Treatment, and Outcomes of Coexistent Pulmonary Hypertension and Interstitial Lung Disease in Systemic Sclerosis.

Authors:  Amber Young; Dharshan Vummidi; Scott Visovatti; Kate Homer; Holly Wilhalme; Eric S White; Kevin Flaherty; Vallerie McLaughlin; Dinesh Khanna
Journal:  Arthritis Rheumatol       Date:  2019-06-18       Impact factor: 10.995

2.  Increased Epicardial Fat Volume Is Independently Associated with the Presence and Severity of Systemic Sclerosis.

Authors:  Benjamin D Long; Jadranka Stojanovska; Richard K J Brown; Anil K Attili; Eizabeth A Jackson; Vladimir Ognenovski
Journal:  Acad Radiol       Date:  2017-08-26       Impact factor: 3.173

3.  Interstitial lung disease increases mortality in systemic sclerosis patients with pulmonary arterial hypertension without affecting hemodynamics and exercise capacity.

Authors:  M Michelfelder; M Becker; A Riedlinger; E Siegert; D Drömann; X Yu; F Petersen; G Riemekasten
Journal:  Clin Rheumatol       Date:  2016-12-27       Impact factor: 2.980

4.  Pulmonary Artery Dimensions as a Prognosticator of Transplant-Free Survival in Scleroderma Interstitial Lung Disease.

Authors:  James Benjamin Gleason; Krunal B Patel; Felix Hernandez; Anas Hadeh; Kristin B Highland; Franck Rahaghi; Jinesh P Mehta
Journal:  Lung       Date:  2017-04-29       Impact factor: 2.584

5.  Clinical Characteristics of Systemic Sclerosis With Interstitial Lung Disease.

Authors:  Eunju Jung; Chang-Hee Suh; Hyoun-Ah Kim; Ju-Yang Jung
Journal:  Arch Rheumatol       Date:  2018-01-15       Impact factor: 1.472

6.  Pulmonary vascular volume is associated with DLCO and fibrotic score in idiopathic pulmonary fibrosis: an observational study.

Authors:  Wen-Jui Wu; Wei-Ming Huang; Chia-Hao Liang; Chun-Ho Yun
Journal:  BMC Med Imaging       Date:  2022-04-23       Impact factor: 2.795

7.  Diversity of hemodynamic types in connective tissue disease associated pulmonary hypertension: more than a subgroup of pulmonary arterial hypertension.

Authors:  Xingbei Dong; Yue Shi; Ying Xia; Xiao Zhang; Junyan Qian; Jiuliang Zhao; Jinmin Peng; Qian Wang; Li Weng; Mengtao Li; Bin Du; Xiaofeng Zeng
Journal:  BMC Pulm Med       Date:  2022-08-01       Impact factor: 3.320

Review 8.  An Overview of Different Techniques for Improving the Treatment of Pulmonary Hypertension Secondary in Systemic Sclerosis Patients.

Authors:  Barbara Ruaro; Francesco Salton; Elisa Baratella; Paola Confalonieri; Pietro Geri; Riccardo Pozzan; Chiara Torregiani; Roberta Bulla; Marco Confalonieri; Marco Matucci-Cerinic; Michael Hughes
Journal:  Diagnostics (Basel)       Date:  2022-03-01
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.